CRTX
+0.0 · +0.00%
GBX · LSE

CRISM Therapeutics Corporation(CRTX) Stock Analysis | Healthcare

GBX --+0.00%
Reward28Low
Risk35Moderate
75%Data
Capital Destroyer
Market Cap:8.91M
ⓘ
Reward Rating
28
Low
Reward Assessment
75% data coverage
Bottom 1% of stocksView factors
ⓘ
Risk Rating
35
Moderate
Risk Assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on CRTX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is CRISM Therapeutics Corporation?

CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs in the British Virgin Islands.

AI Brief Pro

The brief on CRISM Therapeutics Corporation

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is CRISM Therapeutics Corporation?

CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs in the British Virgin Islands. The company's lead product is ChemoSeed, which can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 8.91M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (28)
Company Information
IndustryBiotechnology
Beta0.583
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.